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nally the study was performed as cost-minimization anal-
ysis. The following costs were taken into account: the
drug acquisition price, drug preparation and administra-
tion, medications to treat failures and adverse events, in-
cluding antibiotics added to main medication. Schemes of
treatment for adverse events and choice of antibiotics for
treating clinical failures typical for clinical practice in this
country were obtained from expert panel. Costs of drugs
were derived from official price-lists of pharmacies. Hos-
pital costs were excluded, as there was no difference in
the length of treatment between the groups according to
the results of the trial. RESULTS: According to clinical
trial the probability of clinical success for short-duration
febrile neutropenia treatment in cancer patients is equal
in both drugs (79 % for cefepime and 72% for imi-
penem, equivalence, p  0.0001). Cost of treatment of 1
patient with imipenem-cilastatine including added antibi-
otics, drugs for treating failures and adverse events was
21 207,2 roubles (757,4 USD), for cefepime—10 512, 32
roubles (375,44 USD). CONCLUSION: Cefepime mono-
therapy being clinically as effective as imipenem-cilasta-
tine is twice less costly for the empirical treatment of fe-
ver in short-duration neutropenia. Changing of widely
recommended for empiric therapy of febrile neutropenia
imipenem-cilastatine for cefepime will save 10 694,88
roubles (382 USD) in each treated patient.
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INTRODUCTION and OBJECTIVES: Treatment for
prostate cancer has significant impact on health-related
quality of life (HRQOL). We examine HRQOL in a co-
hort of men who opted for surveillance as initial treat-
ment followed by androgen deprivation therapy (ADT)
and compare them with other treatments. METHODS:
CaPSURE (Cancer of the Prostate Strategic Urologic Re-
search Endeavor) is a national observational database of
men with prostate cancer. We identified a cohort of
newly diagnosed men with prostate cancer who com-
pleted two or more instruments that measure generic and
disease-specific HRQOL. Individuals were grouped by
initial treatment: ADT, surveillance, radical prostatec-
tomy, and radiation therapy. RESULTS: Initial treatment
was as follows: ADT (n  167), surveillance (n  106),
radical prostatectomy (n  351), radiation therapy (n 
75). Sixty-seven men selected surveillance followed by
ADT. Mean age at diagnosis was 73 years with surveil-
lance patients being older. Men had significantly poorer
urinary (decline of 7 points on a 100 point scale) and sex-
ual function (decrease of 10 points) compared with sur-
veillance. HRQOL for ADT, surveillance and radiation
therapy patients changed little over the year following
treatment, while men undergoing radical prostatectomy
showed improvement in all aspects of HRQOL. Scales
are scored from 0–100 with 100  better function and a
difference of 7–10 points is considered clinically signifi-
cant. CONCLUSIONS: Patients receiving ADT had re-
duced energy, poorer sexual and urinary function and
were more bothered by their urine function than patients
undergoing other treatments. Longer follow-up after
start of ADT and surveillance is needed to discern the im-
pact of other factors, including comorbidities.
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OBJECTIVE: To compare paclitaxel (pac) and docetaxel
(doc) in the treatment of second line or greater metastatic
breast cancer using a cost-effectiveness analysis. METH-
ODS: Costs were collected prospectively from 31 patients
in a single outpatient center. Direct medical costs were
collected (e.g., all medications, physician/clinic/labora-
tory visits, ER, hospitalizations, home health care, con-
sultations, special procedures, transfusions, phone calls,
and miscellaneous) and costs were defined using Medi-
care reimbursement rates and AWP for drugs. Effective-
ness measures were obtained from two phase III trials
conducted by Nabholtz. Sensitivity analyses are currently
underway. RESULTS: The average cost per cycle of che-
motherapy was $4,298 and $2,869 for doc and pac re-
spectively. The objective response rates (OR) obtained
for doc and pac in the phase III trials were 30% and 26%
respectively. The cost-effectiveness (CE) ratio for doc is
$14,327 per one-percent increase in OR. The CE ratio
for pac is $11,035 per one-percent increase in OR. An in-
cremental CE analysis suggests that using doc costs
$35,725 per one-percent increase in OR compared to
pac. CONCLUSIONS: The cost-effectiveness ratios sug-
gest that pac is the more cost-effective choice. The incre-
mental cost-effectiveness analysis still supports the use of
pac; however, doc is not out of the standard range of
payment for gains in effectiveness. Physicians and third
party payers should use this information along with cost-
utility studies to help guide decisions on treatment for
metastatic breast cancer patients.
